Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.7.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Revenue:      
Lymphoseek sales revenue $ 17,037,098 $ 10,254,352 $ 4,233,953
Lymphoseek license revenue 1,795,625 1,133,333 300,000
Grant and other revenue 3,136,983 1,861,622 1,740,896
Total revenue 21,969,706 13,249,307 6,274,849
Cost of goods sold 2,297,040 1,754,763 1,586,145
Gross profit 19,672,666 11,494,544 4,688,704
Operating expenses:      
Research and development 8,882,576 12,787,733 16,779,589
Selling, general and administrative 13,013,565 17,257,329 15,542,071
Total operating expenses 21,896,141 30,045,062 32,321,660
Loss from operations (2,223,475) (18,550,518) (27,632,956)
Other income (expense):      
Interest expense, net (14,861,270) (6,873,736) (3,690,068)
Equity in loss of R-NAV, LLC (15,159) (305,253) (523,809)
Loss on disposal of investment in R-NAV, LLC (39,732) 0 0
Change in fair value of financial instruments 2,858,524 (614,782) (1,342,389)
Loss on extinguishment of debt 0 (2,440,714) (2,610,196)
Other, net (27,919) 26,808 72,749
Total other expense, net (12,085,556) (10,207,677) (8,093,713)
Loss before income taxes (14,309,031) (28,758,195) (35,726,669)
Benefit from income taxes 0 436,051 0
Loss from continuing operations (14,309,031) (28,322,144) (35,726,669)
Income from discontinued operations, net of tax effect 0 758,609 0
Net loss (14,309,031) (27,563,535) (35,726,669)
Less loss attributable to noncontrolling interest (648) (855) 0
Deemed dividend on beneficial conversion feature of MT Preferred Stock 0 (46,000) 0
Net loss attributable to common stockholders $ (14,308,383) $ (27,608,680) $ (35,726,669)
(Loss) income per common share (basic and diluted):      
Continuing operations $ (0.09) $ (0.19) $ (0.24)
Discontinued operations 0.00 0.01 0.00
Attributable to common stockholders $ (0.09) $ (0.18) $ (0.24)
Weighted average shares outstanding (basic and diluted) 155,422,384 151,180,222 148,748,396